XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Research and development revenue under collaboration agreement $ 1,185 $ 6,402 $ 8,501 $ 10,168
Revenue from Contract with Customer, Product and Service [Extensible List] us-gaap:InProcessResearchAndDevelopmentMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:InProcessResearchAndDevelopmentMember
Operating expenses:        
Research and development $ 14,654 $ 18,850 $ 45,378 $ 48,682
General and administrative 6,034 5,428 16,632 17,276
Total operating expenses 20,688 24,278 62,010 65,958
Loss from operations (19,503) (17,876) (53,509) (55,790)
Other income (expense):        
Investment income 2,162 550 4,840 1,135
Other expense (2) (12) (8) (13)
Total other income, net 2,160 538 4,832 1,122
Net loss (17,343) (17,338) (48,677) (54,668)
Other comprehensive loss:        
Unrealized gain (loss) on marketable securities 166 (77) (290) (1,181)
Total comprehensive loss $ (17,177) $ (17,415) $ (48,967) $ (55,849)
Net loss per share:        
Net loss per share attributable to common stockholders basic $ (0.4) $ (0.48) $ (1.23) $ (1.51)
Net loss per share attributable to common stockholders diluted $ (0.4) $ (0.48) $ (1.23) $ (1.51)
Weighted-average common stock outstanding, basic 43,437,844 36,257,074 39,688,984 36,165,143
Weighted-average common stock outstanding, diluted 43,437,844 36,257,074 39,688,984 36,165,143